Heart failure definition , classification, etiology, clinical Features, diagnosis, treatment .

Reading File

Finding Sources

Searching PubMed

"heart failure"[MeSH Terms] AND "guidelines"[pt]

Reading File

Searching PubMed

"heart failure"[MeSH Terms] AND "guidelines"

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I now have extensive, authoritative content from multiple top-tier textbooks. Let me compile the comprehensive answer.

Heart Failure: A Comprehensive Overview

1. Definition

Heart failure (HF) is a clinical syndrome resulting from the inability of the heart to meet the metabolic requirements of the body at normal filling pressures. It encompasses a broad range of functional and structural cardiac abnormalities that impair the ability of the ventricle to fill with or eject blood.

Because pulmonary congestion may be absent in many HF patients, the term "heart failure" is preferred over the older term "congestive heart failure."

Textbook of Family Medicine 9e, p. 566

2. Classification

A. By Ejection Fraction (EF-Based)

Type	EF	Mechanism
HFrEF (HF with Reduced EF)	< 40-50%	Reduced LV contraction (systolic dysfunction)
HFmrEF (HF with Mildly Reduced EF)	40-49%	Intermediate, mixed features
HFpEF (HF with Preserved EF)	≥ 50%	Impaired LV filling/relaxation (diastolic dysfunction)
HFimpEF (HF with Improved EF)	Previously reduced, now ≥ 40%	Response to therapy

Important randomized clinical trials to date have enrolled mainly patients with LVEF ≤35-40%, so most evidence-based therapies are proven specifically for HFrEF.

Fuster and Hurst's The Heart, 15th Edition, p. 1511

B. NYHA Functional Classification (Symptom-Based)

Class	Description
Class I	No limitation of physical activity. Ordinary activity does not cause symptoms.
Class II	Slight limitation. Comfortable at rest; ordinary activity causes fatigue, dyspnea, or palpitations.
Class III	Marked limitation. Comfortable at rest; less-than-ordinary activity causes symptoms.
Class IV	Unable to carry out any physical activity without discomfort; symptoms at rest.

First introduced in 1928, the NYHA classification remains in widespread use due to its simplicity at the bedside.

C. ACC/AHA Staging (Progression-Based)

Stage	Description
A	High risk for HF; no structural heart disease or symptoms (e.g., hypertension, diabetes, CAD)
B	Structural heart disease; no symptoms of HF (e.g., asymptomatic LV dysfunction after MI)
C	Structural heart disease WITH prior or current HF symptoms
D	Refractory HF requiring specialized interventions (transplant, LVAD, palliation)

Stages are progressive and not reversible in classification. This system emphasizes prevention at stage A and B.

Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 670; Fuster and Hurst's The Heart, 15th Edition

D. Hemodynamic Classification (Bedside)

Based on perfusion and volume status:

Warm & Dry - compensated, normal perfusion, no congestion
Warm & Wet - congested but adequate perfusion
Cold & Dry - low output, hypovolemia
Cold & Wet - low output AND congestion (worst prognosis)

Indicators of congestion: orthopnea, JVD, rales, hepatojugular reflux, ascites, peripheral edema. Indicators of low perfusion: narrow proportional pulse pressure (<25%), pulsus alternans, cool extremities, impaired mentation.

Fuster and Hurst's The Heart, 15th Edition, p. 1511

E. By Side of Failure

Type	Primary mechanism	Consequences
Left-sided HF	Reduced LV output, elevated left-sided pressures	Pulmonary congestion, pulmonary edema
Right-sided HF	Often secondary to left HF or pulmonary hypertension	Systemic venous congestion, peripheral edema, hepatomegaly
Biventricular HF	Both ventricles affected	Combined features

3. Etiology

Common Causes of Left-Sided HF:

Ischemic heart disease (IHD)/Coronary artery disease - most common cause
Systemic hypertension - causes pressure overload and LV hypertrophy
Mitral or aortic valve disease - volume/pressure overload
Primary myocardial disease - cardiomyopathies (dilated, hypertrophic, restrictive, amyloidosis)
Diabetes mellitus
Congenital heart defects

Common Causes of Right-Sided HF:

Left-sided HF (most common cause of RHF)
Pulmonary hypertension (primary or secondary)
Pulmonary embolism
Chronic obstructive pulmonary disease / cor pulmonale
Tricuspid or pulmonic valve disease
Right ventricular MI

Other/Less Common Causes:

Anemia (high-output HF)
Thyrotoxicosis (high-output HF)
Alcoholic cardiomyopathy
Viral myocarditis
Peripartum cardiomyopathy
Toxins (anthracycline chemotherapy, cocaine)
Infiltrative disease (amyloidosis, sarcoidosis, hemochromatosis)
Arrhythmias (tachycardia-induced cardiomyopathy)
Sleep-disordered breathing (obstructive/central sleep apnea)

Robbins & Kumar Basic Pathology, p. 345; Textbook of Family Medicine 9e, p. 577

4. Pathophysiology

The hemodynamic model of HF has been replaced by the concept of LV remodeling - stretching and dilation with reduction in LV function. Regardless of the initiating injury, neurohormonal mechanisms are activated:

RAAS activation: Angiotensin II promotes myocyte apoptosis, hypertrophy, and fibrosis. Aldosterone augments these effects and promotes adverse remodeling.
Sympathetic nervous system (SNS) activation: Elevated catecholamines cause direct myocardial toxicity and downregulate adrenergic receptors.
Endothelin-1: Produced by dysfunctional endothelium; contributes to vasoconstriction.
Inflammatory cytokines: Exacerbate endothelial dysfunction.
MMPs/TIMPs: Lead to cardiac fibrosis and collagen deposition.
Calcium flux abnormalities and metabolic shifts (glycolysis replacing fatty acid oxidation).

Remodeling is a reversible process with appropriate therapy - this is the basis for using neurohormonal blockers.

5. Clinical Features

Left Heart Failure:

Symptoms (in order of progression):

Dyspnea on exertion - earliest and most significant symptom
Orthopnea - dyspnea in the recumbent position (relieved by sitting/standing); patients sleep semi-upright; measured in "number of pillows"
Paroxysmal nocturnal dyspnea (PND) - dramatic, awakens from sleep with extreme breathlessness
Cough - due to fluid transudation into airspaces
Fatigue and exercise intolerance
Reduced urine output / nocturia

Signs:

Displaced apex beat (LV enlargement)
S3 gallop (volume overload, systolic HF)
S4 gallop (diastolic dysfunction)
Bilateral basal rales/crackles (pulmonary edema)
Pleural effusions (more commonly right-sided)
Tachycardia, narrow pulse pressure
Cool, clammy extremities (low-output states)
Pulsus alternans (severe HF)
Cheyne-Stokes respiration

Right Heart Failure:

Symptoms:

Lower extremity edema
Abdominal distension (ascites)
Vague abdominal pain (hepatic congestion)
Anorexia, nausea
Weight gain

Signs:

Elevated JVP / JVD
Hepatojugular reflux (HJR)
Pitting peripheral edema (ankles, sacrum)
Hepatomegaly (passive congestion), progressing to cardiac cirrhosis, jaundice
Ascites, anasarca
Right-sided S3

Robbins & Kumar Basic Pathology, p. 346-347; Goldman-Cecil Medicine; Frameworks for Internal Medicine

6. Morphological Changes (Pathology)

Heart: LV hypertrophy, often with dilation. LV dilation can cause secondary mitral insufficiency and left atrial enlargement (increasing AF risk). Microscopy shows myocyte hypertrophy with variable interstitial fibrosis.

Lungs: Pulmonary congestion and edema, pleural effusion. Chronic HF produces "heart failure cells" - hemosiderin-laden alveolar macrophages from phagocytosis of extravasated red cells.

Left ventricular hypertrophy: gross pathology shows pressure hypertrophy (thick wall, small cavity), hypertrophied-dilated heart (enlarged chamber), compared to normal. Histology shows increased myocyte size and nuclear size in hypertrophied myocardium.

Fig. 9.1 - Left ventricular hypertrophy. (A) Pressure hypertrophy. (B) LV hypertrophy with/without dilation vs. normal. (C) Normal myocardium. (D) Hypertrophied myocardium - note increased cell and nuclear size. (Robbins & Kumar Basic Pathology)

7. Diagnosis

Diagnostic Criteria (Framingham Criteria)

Diagnosis requires 2 major or 1 major + 2 minor criteria:

Major criteria:

PND or orthopnea
Neck vein distension
Rales
Cardiomegaly on chest X-ray
Acute pulmonary edema
S3 gallop
Increased venous pressure (>16 cmH₂O)
Circulation time >25 sec
Hepatojugular reflux

Minor criteria:

Bilateral ankle edema
Nocturnal cough
Dyspnea on exertion
Hepatomegaly
Pleural effusion
Decrease in vital capacity by 1/3 from maximal
Tachycardia (>120 bpm)

Investigations

Laboratory Tests:

Test	Significance
BNP / NT-proBNP	Key biomarker; elevated in HF; used for diagnosis and monitoring. BNP >100 pg/mL or NT-proBNP >300 pg/mL is supportive
CBC	Detect anemia (contributing cause)
Renal function (BUN/Creatinine)	Baseline; monitor for cardiorenal syndrome
Electrolytes	Especially K⁺ (affected by diuretics/RAAS blockers)
LFTs	Assess hepatic congestion
Thyroid function (TSH)	Rule out thyroid cause
Urinalysis	Proteinuria in advanced HF
Cardiac enzymes (troponin)	Ischemic etiology
HbA1c, lipids	Assess risk factors

ECG:

May show: LVH, old MI changes, LBBB, atrial fibrillation, arrhythmias
Normal ECG makes HF less likely

Chest X-Ray:

Cardiomegaly (cardiothoracic ratio >0.5)
Upper lobe blood diversion
Kerley B lines (interstitial edema)
Bat-wing pulmonary edema
Pleural effusions

Echocardiography (most important investigation):

Gold standard for assessing structure and function
Determines LVEF (differentiates HFrEF vs HFpEF)
Assesses wall motion, valvular disease, pericardial disease
Diastolic function parameters: E/e' ratio >15 indicates high LV filling pressure; e' <8 cm/s (septal) indicates impaired relaxation
Left atrial volume index >34 mL/m² indicates elevated filling pressures

Key echo parameters:

Parameter	Abnormal Value	Implication
LVEF	<50%	Systolic dysfunction
LV end-diastolic diameter	≥60 mm	Volume overload
E/e' ratio	>15	High filling pressure
LA volume index	>34 mL/m²	Chronic elevated filling pressures
TAPSE	<16 mm	RV dysfunction
Tricuspid regurgitation velocity	>3.4 m/s	Pulmonary hypertension

Fuster and Hurst's The Heart, 15th Edition, p. 1511

Additional Investigations (when indicated):

Cardiac MRI - gold standard for myocardial characterization, scar assessment
Coronary angiography - if ischemic etiology suspected
Endomyocardial biopsy - for myocarditis, infiltrative diseases
6-minute walk test / Cardiopulmonary exercise test - functional assessment
Holter monitoring - arrhythmia evaluation

8. Treatment

General Principles: ABCDE Approach

Identify and treat the underlying cause (ischemia, hypertension, valvular disease)
Identify and treat precipitating factors (infections, arrhythmias, medication non-compliance, excess salt/fluid intake)
Neurohormonal blockade is the cornerstone of HFrEF therapy

A. Non-Pharmacological Measures (All Stages)

Salt restriction: <2-3 g sodium/day
Fluid restriction: ~1.5-2 L/day in severe HF
Daily weight monitoring (>2 kg gain in 3 days = seek care)
Regular aerobic exercise (stable patients) - proven to increase exercise capacity
Smoking cessation, alcohol abstinence
Vaccination (influenza, pneumococcal)
Cardiac rehabilitation

B. Pharmacological Treatment

HFrEF (LVEF <40%) - The "Fantastic Four" / GDMT (Guideline-Directed Medical Therapy)

1. ACE Inhibitors (ACEi) - First-line Reduce mortality and morbidity. Block RAAS; prevent adverse remodeling.

Drug	Starting dose	Target dose
Enalapril	2.5 mg BID	10-20 mg BID
Lisinopril	2.5-5 mg QD	20-40 mg QD
Ramipril	2.5 mg BID	5 mg BID
Captopril	6.25-12.5 mg TID	50 mg TID

2. ARBs (for ACEi-intolerant patients, e.g., ACEi cough)

Candesartan, Valsartan, Losartan

3. ARNI (Angiotensin Receptor-Neprilysin Inhibitor)

Sacubitril/Valsartan (LCZ696) - superior to ACEi (enalapril) in reducing CV death and HF hospitalization (PARADIGM-HF trial). Replaces ACEi in tolerated patients with HFrEF. Must have a 36-hour washout from ACEi before starting.

4. Beta-Blockers (BB) Initiated only in clinically stable patients, at very low doses (1/8 target dose), titrated every 4 weeks. Improve LV function over 3-6 months.

Drug	Starting dose	Target dose	Notes
Carvedilol	3.125 mg BID	25 mg BID (50 mg if >85kg)	Non-selective; vasodilation
Metoprolol succinate CR/XL	12.5 mg QD	200 mg QD	Beta-1 selective; zero-order release required
Bisoprolol	1.25 mg QD	10 mg QD	Beta-1 selective; long t½

Do NOT start in acutely decompensated HF
If hospitalized while on BB, reduce dose or hold; restart once stable

5. Mineralocorticoid/Aldosterone Receptor Antagonists (MRA)

Spironolactone 25-50 mg/day, Eplerenone 25-50 mg/day
Reduce mortality in NYHA II-IV HFrEF (RALES, EPHESUS trials)
Monitor K⁺ and renal function closely; contraindicated if K⁺ >5.0 or eGFR <30

6. SGLT2 Inhibitors (the newest pillar)

Dapagliflozin (DAPA-HF) and Empagliflozin (EMPEROR-Reduced): Reduce CV death and HF hospitalization regardless of diabetes status. Now recommended in all HFrEF patients.

7. Diuretics (for symptom relief/congestion)

Loop diuretics (furosemide, bumetanide, torsemide) - mainstay for decongestion
Thiazides (metolazone) - add for diuretic resistance
Do NOT reduce mortality; improve symptoms and exercise tolerance

8. Ivabradine

If-channel inhibitor; reduces heart rate in sinus rhythm (HR ≥70 bpm) despite max BB therapy
Reduces HF hospitalization

9. Hydralazine + Isosorbide Dinitrate

For patients who cannot tolerate ACEi/ARB/ARNI (e.g., severe renal impairment)
Proven mortality benefit specifically in Black patients (A-HeFT trial)

10. Digoxin

Reduces HF hospitalization; no mortality benefit
Used for rate control in AF or persistent symptoms despite optimal therapy
Narrow therapeutic index; monitor levels

HFpEF - Limited proven therapies

SGLT2 inhibitors (empagliflozin - EMPEROR-Preserved; dapagliflozin - DELIVER trial) - recently shown to reduce HF hospitalizations in HFpEF
Diuretics for congestion relief
Treat underlying causes: control hypertension, AF rate control, ischemia management
No proven mortality-reducing pharmacotherapy equivalent to HFrEF exists for HFpEF

C. Device Therapy

1. Implantable Cardioverter-Defibrillator (ICD)

For primary prevention of sudden cardiac death in HFrEF patients with LVEF ≤35%, NYHA II-III, on optimal medical therapy for ≥3 months, with life expectancy >1 year

2. Cardiac Resynchronization Therapy (CRT)

For patients with LVEF ≤35%, LBBB with QRS ≥150 ms (≥130 ms in some guidelines), NYHA II-IV on optimal medical therapy
CRT-D (defibrillator combined): for those also meeting ICD criteria
Improves LV function, symptoms, and survival; reverses remodeling

3. Left Ventricular Assist Device (LVAD)

Bridge to transplant or destination therapy for Stage D HF
Continuous-flow devices are standard

4. Cardiac Transplantation

Gold standard for end-stage HF (Stage D)
Indication: refractory HF with poor prognosis, no contraindications
1-year survival ~85%; 5-year survival ~70%

D. Treatment of Acute Decompensated HF (ADHF)

Immediate measures:

Oxygen / NIV (CPAP/BiPAP) for hypoxia/pulmonary edema
IV loop diuretics (furosemide): rapid decongestion; double the oral dose as IV
Vasodilators (IV nitroglycerin, nitroprusside): reduce preload/afterload in hypertensive patients
Inotropes (dobutamine, dopamine): for cardiogenic shock / severely reduced cardiac output
Intra-aortic balloon pump (IABP): mechanical circulatory support in cardiogenic shock
Monitor urine output, renal function, electrolytes closely
Treat precipitating factors (infection, ACS, arrhythmia, hypertensive crisis)

Summary Table: Drugs Proven to Reduce Mortality in HFrEF

Drug Class	Example	Benefit
ACEi/ARB/ARNI	Enalapril, Sacubitril-Valsartan	↓ Mortality ~20-30%
Beta-blockers	Carvedilol, Metoprolol succinate, Bisoprolol	↓ Mortality ~30-35%
MRA	Spironolactone, Eplerenone	↓ Mortality ~15-30%
SGLT2 inhibitors	Dapagliflozin, Empagliflozin	↓ CV death/HF hospitalization
Hydralazine/Nitrate	H-ISDN	↓ Mortality (Black patients)

Recent Guideline Updates (2025)

The iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025 (PMID: 40533340) and updated ASE recommendations for HFpEF diagnosis (PMID: 40617625) reinforce the "fantastic four" GDMT for HFrEF (ARNI/ACEi, BB, MRA, SGLT2i) and expand SGLT2i indication to HFpEF.

Sources:

Textbook of Family Medicine, 9th Edition (Hunt et al.)
Robbins & Kumar Basic Pathology
Fuster and Hurst's The Heart, 15th Edition
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Braunwald's Heart Disease, 2-Volume Set
Goldman-Cecil Medicine, International Edition

This is a shared conversation. Sign in to Orris to start your own chat.